psychopharmacology – mycolab.ai

Drug–drug interactions involving classic psychedelics: A systematic review

mycolabadmin

This review examined how psychedelic drugs like LSD and psilocybin interact with other medications people might be taking. Researchers found that certain psychiatric medications like antipsychotics can block the effects of psychedelics, while other drugs may enhance them. The study highlights the importance of understanding these interactions for safe therapeutic use of psychedelics in clinical settings.

Associations Between Escitalopram and Psilocybin Therapy and Brain Resting-State Functional Connectivity in Major Depressive Disorder

mycolabadmin

This study compared how two depression treatments—a common antidepressant called escitalopram and psilocybin therapy—affect brain connectivity and depression symptoms. Both treatments reduced feelings of lacking pleasure and impulsive behaviors in depressed patients. The research found that while both worked, they affected different parts of the brain’s reward system in distinct ways, suggesting they may work through different mechanisms.

Exploring the Therapeutic Potential of Ketamine and Psilocybin in Comparison to Current Treatment Regimens for Treatment-Resistant Depression, Mood Disorders, and Post-traumatic Stress Disorder in the Pediatric Population: A Narrative Review

mycolabadmin

This review examines two emerging psychiatric treatments—ketamine and psilocybin—for treating hard-to-treat mental health conditions in children and teenagers. Both work by affecting brain chemicals differently than traditional medications and can provide rapid symptom relief, sometimes within hours or days rather than weeks. The study found promising results for depression, anxiety, PTSD, and bipolar disorder, though researchers emphasize that more studies are needed to ensure these treatments are safe for developing brains and that careful ethical guidelines must be established.

Social acceptability of psilocybin-assisted therapy for existential distress at the end of life: A population-based survey

mycolabadmin

This study surveyed 2,800 Canadians about their views on using psilocybin (a psychedelic compound from certain mushrooms) to help patients with terminal illnesses manage existential distress and anxiety. About 79% of respondents thought it was a reasonable medical option, and 85% believed the government should cover the costs. People who had previous experience with psilocybin, those exposed to palliative care, and those with progressive political views were most supportive of this therapy.

Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees

mycolabadmin

This study followed 52 people who attended psilocybin retreats in the Netherlands and measured their anxiety levels before, one day after, and one week after the experience. Participants showed significant reductions in both immediate anxiety (state anxiety) and long-term anxiety tendencies (trait anxiety) that lasted up to a week. The anxiety improvements were most strongly linked to feeling a sense of ego dissolution during the experience and to lasting changes in personality traits, particularly becoming less neurotic.

Psilocybin-induced modulation of visual salience processing

mycolabadmin

When people take psilocybin mushrooms, they look at images differently – they focus more on visually striking regions while keeping their eyes in smaller areas. Brain recordings showed changes in electrical activity patterns. The research suggests psilocybin alters how the brain balances what naturally catches attention versus where we intentionally choose to look.

Premorbid characteristics of the SAPAP3 mouse model of obsessive-compulsive disorder: behavior, neuroplasticity, and psilocybin treatment

mycolabadmin

This research examined young genetically modified mice that lack the SAPAP3 gene to understand early signs of obsessive-compulsive disorder-like behavior. The study found that these juvenile mice showed anxiety-like behaviors before developing the excessive grooming typical of the adult model. Surprisingly, psilocybin treatment—which works in adult mice—did not help reduce anxiety in the younger mice, suggesting that the brain needs to mature for this treatment to be effective.

Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) – Rationale and study design

mycolabadmin

This research paper describes a major clinical trial testing whether psilocybin (the active compound in magic mushrooms) can treat depression that doesn’t respond to standard medications. The trial involves 144 patients receiving either psilocybin at different doses or a placebo in a carefully controlled medical setting with psychological support. The researchers developed special methods to address unique challenges in psychedelic research, such as making it difficult for patients to guess whether they received the active drug, and ensuring all patients eventually get access to the potentially helpful treatment.

Anhedonia: Current and future treatments

mycolabadmin

Anhedonia is the inability to feel pleasure from activities, which is a significant problem affecting many people with depression and other psychiatric conditions. This review examined many different treatments for anhedonia including medications, brain stimulation techniques, and psychological therapies. The research shows that newer medications like vortioxetine and ketamine work better for anhedonia than older antidepressants, and combining multiple approaches including therapy and lifestyle changes gives the best results.

Acute and Chronic Psilocybin in Mouse Models of Psychiatric Disorders

mycolabadmin

Researchers tested psilocybin (the active compound in magic mushrooms) in mice bred to show obsessive-compulsive behaviors. A single dose of psilocybin reduced compulsive grooming for about a week, but giving it repeatedly over time did not help with anxiety, depression, or compulsive behaviors. The findings suggest psilocybin might work best as a one-time treatment rather than repeated doses, which has implications for how these drugs might be used in future psychiatric treatment.

Research Topic: psychopharmacology